Back to top
more

Karyopharm Therapeutics (KPTI)

(Delayed Data from NSDQ)

$1.06 USD

1.06
660,655

0.00 (0.00%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.05 -0.01 (-0.94%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for KPTI

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Karyopharm Therapeutics Inc. [KPTI]

Reports for Purchase

Showing records 261 - 280 ( 386 total )

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 261

11/09/2018

Company Report

Pages: 8

Upgrading to OUTPERFORM: Expect Positive SADAL Data at ASH; Approval Next April

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 262

11/07/2018

Daily Note

Pages: 3

Karyopharm Receives FDA Fast Track Designation for Selinexor in Relapsed DLBCL

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 263

11/05/2018

Industry Report

Pages: 14

UPDATED: ASH 2018 Abstract Roundup and Schedule for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 264

11/05/2018

Industry Report

Pages: 14

CORRECTED: ASH 2018 Abstract Roundup and Schedule for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 265

11/02/2018

Daily Note

Pages: 4

Karyopharm to Present Data Including Phase 2b SADAL Top-line at ASH 2018

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 266

10/08/2018

Company Report

Pages: 8

Selinexor Granted Priority Review; PDUFA Date April 6, 2019

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 267

09/14/2018

Company Report

Pages: 8

Updates Positive Phase 2b STORM Data in MM at SOHO; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 268

08/29/2018

Daily Note

Pages: 3

Karyopharm to Present Additional Phase 2b STORM Data at SOHO Meeting in September

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 269

08/15/2018

Industry Report

Pages: 15

PacGrow Healthcare Conference: Day 1 Recap

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 270

08/08/2018

Daily Note

Pages: 11

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 271

08/08/2018

Company Report

Pages: 8

Uncertain Market Outlook for Sel makes this a Wait-and-See Story

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 272

08/07/2018

Company Report

Pages: 5

Karyopharm Reports 2Q18 Results; Rolling NDA Submission Complete

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 273

07/18/2018

Daily Note

Pages: 3

Karyopharm Initiates Rolling NDA Submission for Selinexor; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 274

06/15/2018

Daily Note

Pages: 4

Positive Selinexor STOMP Multiple Myeloma Data Update at EHA

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 275

06/05/2018

Industry Report

Pages: 10

Biotechnology -ASCO Presentations Roundup

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 276

05/24/2018

Company Report

Pages: 7

KPTI Out-licenses Selinexor, Eltanexor, Verdinexor and KPT-9274 in China and Other Asia Countries

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 277

05/24/2018

Company Report

Pages: 8

Downgrading to NEUTRAL, Shares Fully Valued Here, in Our View

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 278

05/24/2018

Daily Note

Pages: 6

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 279

05/17/2018

Industry Report

Pages: 6

Biotechnology -ASCO Abstract Roundup

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Karyopharm Therapeutics Inc.

Industry: Medical - Drugs

Record: 280

05/17/2018

Company Report

Pages: 8

ASCO Abstracts Released for Selinexor

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party